Jounce Therapeutics to Present at Cowen and Company 38th Annual Health Care Conference
05 mars 2018 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Thursday, March 8, 2018
01 mars 2018 16h52 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., March 01, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
03 janv. 2018 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Added to NASDAQ Biotechnology Index
14 déc. 2017 07h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Present at BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference
07 déc. 2017 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Reports Third Quarter 2017 Financial Results
13 nov. 2017 06h30 HE
|
Jounce Therapeutics, Inc.
- Remain on track to announce preliminary efficacy data for the Phase 1/2 ICONIC study in 1H 2018 - - Strengthen leadership team and board with key new appointments - - Update full year financial...
Jounce Therapeutics to Present at the Stifel 2017 Healthcare Conference
09 nov. 2017 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Announce Third Quarter 2017 Financial Results and Host Conference Call on Monday, November 13, 2017
08 nov. 2017 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Present Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
07 nov. 2017 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Appoints Luis A. Diaz, Jr., M.D., to its Board of Directors
23 oct. 2017 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...